Who owns PSYENCE BIOMEDICAL LTD. (PBMWW)? Elite investor 13F holders
3 tracked elite investors reported holding PSYENCE BIOMEDICAL LTD as of 2026-06-30, including Saba Capital, D.E. Shaw, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital | PSYENCE BIO WARRENTS | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 7238.00 USD | 297847.000000 | Shares | hold | Original filing |
| D.E. Shaw | PSYENCE BIO WARRENTS | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3682.00 USD | 175352.000000 | Shares | hold | Original filing |
| Ancora Advisors / Ancora Holdings | PSYENCE BIO WARRENTS | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 121.00 USD | 5000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.